PE

Peptron, Inc.

A biotech firm developing sustained-release peptide drugs using proprietary technology.

087010 | KO

Overview

Corporate Details

ISIN(s):
KR7087010005
LEI:
Country:
South Korea
Address:
대전광역시 유성구 유성대로1628번길 37-24, 대전광역시

Description

Peptron, Inc. is a biotechnology company specializing in peptide engineering and the development of sustained-release (SR) medications. The company's core focus is its proprietary SmartDepot platform technology, which enables the long-acting formulation of peptide-based drugs to treat chronic and life-threatening disorders. A key area of development is in neurodegenerative diseases, with a notable pipeline candidate being a sustained-release formulation of exenatide, based on patents exclusively licensed from the NIH. Peptron operates its own GMP-compliant manufacturing facility to produce its SR formulations, supporting its progression from pre-clinical research to commercial-stage development.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-03-12 00:00
[기재정정]의결권대리행사권유참고서류
Korean 126.6 KB
2025-03-11 00:00
주주총회소집결의
Korean 15.0 KB
2025-03-11 00:00
주주총회집중일개최사유신고
Korean 5.2 KB
2025-03-11 00:00
주주총회소집공고
Korean 115.5 KB
2025-03-11 00:00
의결권대리행사권유참고서류
Korean 122.4 KB
2025-02-27 00:00
기타시장안내 (시장평가 우수기업 매출액 특례적용 관련)
Korean 2.7 KB
2025-02-13 00:00
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 11.5 KB
2024-12-19 00:00
주식등의대량보유상황보고서(일반)
Korean 93.9 KB
2024-12-16 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.2 KB
2024-12-16 00:00
현금ㆍ현물배당을위한주주명부폐쇄(기준일)결정
Korean 5.9 KB
2024-11-27 00:00
주식등의대량보유상황보고서(일반)
Korean 125.7 KB
2024-11-27 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 22.4 KB
2024-11-27 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 22.5 KB
2024-11-21 00:00
증권발행실적보고서
Korean 179.6 KB
2024-11-21 00:00
증권발행결과(자율공시)
Korean 7.4 KB

Automate Your Workflow. Get a real-time feed of all Peptron, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Peptron, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Peptron, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.